Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?
about
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Treatment options in patients with metastatic gastric cancer: current status and future perspectivesLymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery.
P2860
Q30313895-D65A97D7-091E-46C3-AFAD-C72A5F20E1BDQ33389519-F3386945-CB3B-4652-8E62-7C3D9742CE6FQ33407676-DE492677-92C4-4C31-92A4-93A78F1AB452Q33759177-ABB7E316-1020-4A4B-8AFA-081B4035CC3CQ33889468-7A370208-37C9-4398-9724-49E1750C0E2DQ34661367-FABE15FA-7549-4615-B3AB-08F6735584F0Q37047634-337638AC-E986-4084-ABB1-EAB08FC0082FQ37301478-CBB69BDC-A265-4E15-8AA5-B4661FF83EBBQ38268000-4CA0F3F0-827C-4903-B75E-84E6D2CB92A1Q43205907-7A2C2E86-3AB6-4F06-86DF-51A292899620Q43236139-A87BF81B-A424-482D-8114-B593FFF26D3CQ43830000-9FAD741C-A01C-4720-953B-9D693F6CA4C0Q51836775-42984179-E31B-4B3D-855D-1B964E07F819Q54218339-38D61E56-64CD-469F-9C41-962CE9F181DDQ54606278-5E80E1C6-27F9-44FB-9907-59F85FD7B9A2
P2860
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Coexpression of receptor-tyros ...... molecular targeting strategy?
@en
Coexpression of receptor-tyros ...... molecular targeting strategy?
@nl
type
label
Coexpression of receptor-tyros ...... molecular targeting strategy?
@en
Coexpression of receptor-tyros ...... molecular targeting strategy?
@nl
prefLabel
Coexpression of receptor-tyros ...... molecular targeting strategy?
@en
Coexpression of receptor-tyros ...... molecular targeting strategy?
@nl
P2093
P2860
P356
P1476
Coexpression of receptor-tyros ...... molecular targeting strategy?
@en
P2093
Andreas Teufel
Annett Müller
Carl C Schimanski
Daniel Drescher
Friedrich Dünschede
Ines Gockel
Kerstin Herzer
Kirsten Frerichs
Markus Moehler
Martin Holtmann
P2860
P304
P356
10.3748/WJG.V13.I26.3605
P407
P577
2007-07-01T00:00:00Z